Premium
Epipodophyllotoxin‐related leukemia. Identification of a new subset of secondary leukemia
Author(s) -
Whitlock James A.,
Greer John P.,
Lukens John N.
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910801)68:3<600::aid-cncr2820680326>3.0.co;2-f
Subject(s) - teniposide , medicine , leukemia , etoposide , chemotherapy , oncology , acute myelomonocytic leukemia , immunology
Thirty‐seven children and adults who developed acute nonlymphocytic leukemia after the administration of chemotherapy that included etoposide or teniposide for a variety of hematologic and solid malignancies were identified. The secondary leukemia that occurred in these patients could be distinguished from the secondary leukemia that occurs after treatment with alkylating agents by the following: a shorter latency period; a predominance of monocytic or myelomonocytic features; and frequent cytogenetic abnormalities involving 11q23. Patients receiving an epipodophyllotoxin are at risk for developing secondary leukemia that has features distinct from the syndrome of secondary leukemia associated with alkylating agents.